UBS Group
ARDS

UBS Group’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

UBS Group’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,683
Closed -$842 – 10216
2023
Q1 		$842 Sell
2,683
-4,985
-65% -$3.62K ﹤0.01% 8889
2022
Q4 		$9.05K Buy
7,668
+4,471
+140% +$4.32K ﹤0.01% 8696
2022
Q3 		$3K Sell
3,197
-5,096
-61% -$7.92K ﹤0.01% 9646
2022
Q2 		$9K Buy
+8,293
New +$10.3K ﹤0.01% 8220
2021
Q3 		– Sell
-3,229
Closed -$24K – 10361
2021
Q2 		$24K Buy
+3,229
New +$20.2K ﹤0.01% 7167
2021
Q1 		– Sell
-454
Closed -$3K – 9664
2020
Q4 		$3K Sell
454
-131
-22% -$915 ﹤0.01% 8041
2020
Q3 		$4K Sell
585
-764
-57% -$5.33K ﹤0.01% 7462
2020
Q2 		$9K Buy
+1,349
New +$9.31K ﹤0.01% 7109
2020
Q1 		– Sell
-734
Closed -$3K – 8563
2019
Q4 		$3K Sell
734
-291
-28% -$1.53K ﹤0.01% 7779
2019
Q3 		$7K Sell
1,025
-1,038
-50% -$9.5K ﹤0.01% 7364
2019
Q2 		$21K Buy
2,063
+412
+25% +$3.96K ﹤0.01% 6585
2019
Q1 		$19K Sell
1,651
-375
-19% -$3.46K ﹤0.01% 6365
2018
Q4 		$22K Buy
2,026
+217
+12% +$2.48K ﹤0.01% 6717
2018
Q3 		$24K Buy
+1,809
New +$23.4K ﹤0.01% 6706

Other funds holding ARDS

Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group's ARDS Position: Q2 2023 in Review

UBS Group sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q2 2023, closing a stake of 2,683 shares — an estimated $842 sold.

UBS Group first reported a position in ARDS in Q3 2018 and held it in 14 quarters. The position peaked at $24K in Q2 2021. 18 funds tracked by Wall St. Rank hold ARDS as of Q2 2023.

  • UBS Group reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 2,683 Aridis Pharmaceuticals Inc. Common Stock shares in Q2 2023, an estimated $842.
  • UBS Group first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2018 and held it in 14 quarters.
  • UBS Group's Aridis Pharmaceuticals Inc. Common Stock position peaked at $24K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.